home / stock / sqz / sqz news


SQZ News and Press, SQZ Biotechnologies Company From 03/16/22

Stock Information

Company Name: SQZ Biotechnologies Company
Stock Symbol: SQZ
Market: NYSE

Menu

SQZ SQZ Quote SQZ Short SQZ News SQZ Articles SQZ Message Board
Get SQZ Alerts

News, Short Squeeze, Breakout and More Instantly...

SQZ - SQZ Biotechnologies GAAP EPS of -$2.49 beats by $0.26, revenue of $27.1M beats by $5.22M

SQZ Biotechnologies press release (NYSE:SQZ): FY GAAP EPS of -$2.49 beats by $0.26. Revenue of $27.1M (+29.1% Y/Y) beats by $5.22M. As of December 31, 2021, the company had cash and cash equivalents of $143.5 million and anticipates this will be sufficient to fund operating expenses and capit...

SQZ - SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates

SQZ-PBMC-HPV-101 Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient as Demonstrated in December 2021 ESMO-IO Oral Presentation DSMB Recommended SQZ-PBMC-HPV-101 Advance Into Combination Stage with Checkpoint Inhib...

SQZ - SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company’s enhanced antigen presenting cell (eAPC) platform at the American Assoc...

SQZ - AlloVir: A Comparative Study Of Its Manufacturing Process

AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need. For further de...

SQZ - SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC's Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

Multiple Immune Cell Types – T cells, B cells, NK cells, and Monocytes – Demonstrate Engineering of MHC-I Antigen Presentation Paper on the Company’s Cell Squeeze® Platform’s Cell Engineering Capabilities Published in the February 15th Edition of Jou...

SQZ - SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors

SQZ® Enhanced APCs (eAPCs) Build on Promising Initial SQZ® APC Monotherapy Clinical Data by Broadening the Addressable Patient Population and Incorporating Enhanced Immunological Functions to Increase Potency SQZ eAPCs are Created by Delivery of Multiple mRNAs Encodi...

SQZ - SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor. “John is an iconic b...

SQZ - SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

Patient’s Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflame...

SQZ - SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidat...

SQZ - SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China

Roche Accelerator Membership to Support Company’s Early Strategic Planning and Market Exploration in China SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initia...

Previous 10 Next 10